Gallbladder Adenocarcinoma — Trials

Gallbladder Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

17 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 4
Recruiting: 2
Ph III recruiting: 1
Growth YoY: —
Industry share: 0%
Top sponsor: ECOG-ACRIN Cancer Research Group
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (5)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03267940	Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma	terminated	Phase 1	85	Halozyme TherapeuticsINDUSTRY	3	Feb 7, 2020	clinicaltrials
NCT00478140	Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery	terminated	Phase 2	4	National Cancer Institute (NCI)